Nykode Therapeutics AS (VACBF) Stock Price, News & Analysis

Company Overview

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.

Key Stats

• Today's Range: $0.32 to $0.32
• 50-Day Range: $0.32 to $0.53
• 52-Week Range: $0.32 to $0.95
• Volume: N/A
• Average Volume: 1,000 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VACBF Stock Analysis - Frequently Asked Questions

How have VACBF shares performed this year?

Nykode Therapeutics AS's stock was trading at $1.58 on January 1st, 2024. Since then, VACBF stock has decreased by 80.1% and is now trading at $0.3150.
View the best growth stocks for 2024 here.

How do I buy shares of Nykode Therapeutics AS?

Shares of VACBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:VACBF
• CUSIP: N/A
• CIK: N/A
• Web: nykode.com
• Phone: 47-22-95-81-93
• Fax: N/A
• Employees: 171
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A